CryoLife

Artivion, Inc. focuses on developing solutions that address cardiac and vascular surgeons' clinical challenges in treating patients with aortic diseases. Its products include aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts, and surgical sealants. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes aortic stents and stent grafts, surgical sealants, and On-X products. The Preservation Services segment provides cardiac and vascular tissue preservation services. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Artivion, Inc. engages in the research and development of solutions which address cardiac and vascular surgeons' clinical challenges in treating patients with aortic diseases. Its products include aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts, and surgical sealants. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes aortic stents and stent grafts, surgical sealants, and On-X products. The Preservation Services segment offers cardiac and vascular tissue preservation services. The company was founded on January 19, 1984, and is headquartered in Kennesaw, GA.

ATLANTA, Jan. 18, 2022 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it was renaming and rebranding itself to Artivion, Inc., effective immediately. Derived from the words "aorta", "innovation", and "vision", the company's new name and brand reflect its evolution to focus on providing innovative technologies to surgeons who treat patients with aortic disease.

CryoLife Announces Corporate Rebranding and Changes Name to Artivion

Archrock

Value investors may find the following stocks to be attractive opportunities, as they have low price-sales ratios compared to the S&P 500 and good profitability.

A Trio of Low Price-Sales Ratio Stocks

ATLANTA, Nov. 9, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that members of management will host one-on-one meetings at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Services Forum on Thursday, November 18, 2021. Due to the format of this event no webcast will be available.

CryoLife to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum

The mean of analysts' price targets for CryoLife (CRY) points to a 50.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think CryoLife (CRY) Could Surge 51%: Read This Before Placing a Bet

CryoLife, Inc. (CRY) CEO J. Patrick Mackin on Q3 2021 Results - Earnings Call Transcript

CryoLife (CRY) delivered earnings and revenue surprises of 420.00% and -0.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

CryoLife (CRY) Tops Q3 Earnings Estimates

Cryolife (NYSE:CRY) reported its Q3 earnings results on Thursday, November 4, 2021 at 04:05 PM. Here's what investors need to know about the announcement.

Recap: Cryolife Q3 Earnings

ATLANTA, Nov. 4, 2021 /PRNewswire/ -- Third Quarter and Recent Business Highlights: Achieved total revenues of $72.2 million in the third quarter 2021 versus $65.1 million in the third quarter of 2020, an increase of 11% on a GAAP basis and 9% on a non-GAAP proforma constant currency basis Net income was $10.6 million, or $0.26 per share, in the third quarter of 2021 Non-GAAP net loss was ($1.2) million, or ($0.03) per share, in the third quarter of 2021 CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its financial results for the third quarter ended September 30, 2021. "Despite meaningful headwinds from the Delta variant in the third quarter, we still generated revenue growth on both a GAAP and pro forma constant currency basis compared to the prior year and compared to 2019, driven by our recent product launches and strength in our U.S. On-X aortic valve business.

CryoLife Reports Third Quarter 2021 Financial Results

CryoLife (CRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: CryoLife (CRY) Q3 Earnings Expected to Decline

ATLANTA, Oct. 20, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2021 financial results will be released on Thursday, November 4, 2021 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.

CryoLife Announces Release Date and Teleconference Call Details for Third Quarter 2021 Financial Results

ATLANTA, Sept. 22, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today the appointment of Anthony "Tony" Semedo to its Board of Directors effective October 1, 2021.

Anthony Semedo Joins CryoLife Board of Directors

ATLANTA, Aug. 31, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021. The Company's virtual fireside chat is scheduled to begin at 12:30 p.m.

CryoLife to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

ATLANTA, Aug. 2, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in two upcoming virtual investor conferences. CryoLife's management team will present at the upcoming Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11, 2021.

CryoLife to Participate in Upcoming Virtual Investor Conferences

CryoLife, Inc. (CRY) CEO Pat Mackin on Q2 2021 Results - Earnings Call Transcript

CryoLife (CRY) delivered earnings and revenue surprises of -20.00% and 5.76%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

CryoLife (CRY) Reports Q2 Loss, Tops Revenue Estimates

Shares of Cryolife (NYSE:CRY) rose 2.9% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 700.00% year over year to $0.12, which beat the estimate of ($0.05).

Cryolife: Q2 Earnings Insights

ATLANTA, July 29, 2021 /PRNewswire/ -- Second Quarter and Recent Business Highlights: Achieved total revenues of $76.1 million in the second quarter 2021 versus $53.8 million in the second quarter of 2020, an increase of 42% on a GAAP basis and 35% on a non-GAAP proforma constant currency basis Net loss was ($2.2) million, or ($0.06) per share, in the second quarter of 2021 Non-GAAP net income was $4.8 million, or $0.12 per share, in the second quarter of 2021  CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its financial results for the second quarter ended June 30, 2021. "For the second consecutive quarter we saw revenue growth on both a GAAP and pro forma constant currency basis compared to the prior year, and more importantly compared to 2019.

CryoLife Reports Second Quarter 2021 Financial Results

Baxter

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, announced its Baxter Healthcare Corporation subsidiary has completed the acquisition of certain assets related to PerClot Polysaccharide Hemostatic System from CryoLife, Inc (NYSE:CRY) for up to $60.8 million, including $25 million paid upfront. The remainder will be paid out upon achievement of certain select milestones. The transaction reinforces Baxter's strategy of acquiring pr

Baxter Announces Acquisition of PerClot Polysaccharide Hemostatic System to Expand Advanced Surgery Portfolio

ATLANTA, July 29, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has completed the sale of its PerClot product line to a subsidiary of Baxter International, Inc. ("Baxter") (NYSE: BAX ), for up to $60.8 million in cash. Of the $60.8 million, CryoLife will receive up to $45.8 million and Starch Medical, Inc. ("SMI") will receive up to $15.0 million.

CryoLife Announces Sale of PerClot to Baxter

CryoLife (CRY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CryoLife (CRY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

ATLANTA, July 15, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2021 financial results will be released on Thursday, July 29, 2021 after the market closes.  On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.

CryoLife Announces Release Date and Teleconference Call Details for Second Quarter 2021 Financial Results

ATLANTA, May 18, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming UBS Global Healthcare Virtual Conference on Tuesday, May 25, 2021. The Company's virtual fireside chat is scheduled to begin at 11:00 a.m.

CryoLife to Participate in the UBS Global Healthcare Virtual Conference

CryoLife continues to perform on recent fundamental and technical momentum, where shareholders have enjoyed +25% upside YTD.

CryoLife, Inc.: Regulatory Tailwinds For FY2021, 23% Upside Potential

CryoLife (CRY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

CryoLife (CRY) Soars 24.2%: Is Further Upside Left in the Stock?

CryoLife, Inc. (CRY) CEO Pat Mackin on Q1 2021 Results - Earnings Call Transcript

News for CryoLife Stock (CRY)